Skip to main content
SpringerLink
Log in

Circulating levels of adropin and overweight/obesity: a systematic review and meta-analysis of observational studies

  • Review Article
  • Published:
Hormones Aims and scope Submit manuscript

Abstract

The association between circulating adropin levels and overweight/obesity is currently unclear. The aim of this study was thus to investigate and seek to determine the association between circulating adropin levels and overweight/obesity using the meta-analysis approach of observational studies. A comprehensive literature search was carried out through the PubMed, Web of Science, and SCOPUS databases to identify relevant observational studies that assessed the relationship between circulating adropin levels and overweight/obesity up to September 2020. A random-effects model was used to compute the pooled weighted mean difference (WMD) with 95% confidence intervals (CI). The meta-analysis of five studies (n = 643 participants) showed that circulating adropin levels were significantly lower in the overweight/obese vs. the normal-weight participants (WMD =  − 0.96 ng/ml, 95% CI =  − 1.72 to − 0.19, P = 0.01; I2 = 88.4%). In subgroup analyses, lower circulating adropin levels in obese participants compared with normal-weight were observed in Asians (WMD =  − 1.58 ng/ml, 95% CI =  − 1.96 to − 1.21, P < 0.001; I2 = 0.00%), and in patients with metabolic disorders (WMD =  − 1.26 ng/ml, 95% CI =  − 1.76 to − 0.77, P < 0.001; I2 = 44.6%), respectively. Circulating adropin levels were significantly lower in overweight/obese vs. normal-weight participants, suggesting a possible role of this hormone in the development of obesity. However, the present research indicates that further studies are needed to conclusively confirm whether adropin is a viable marker of obesity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Data are available on request from the corresponding author.

References

  1. Jaacks LM, Vandevijvere S, Pan A et al (2019) The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol 7:231–240. https://doi.org/10.1016/s2213-8587(19)30026-9

    Article  PubMed  PubMed Central  Google Scholar 

  2. Aydin S (2014) Three new players in energy regulation: preptin, adropin and irisin. Peptides 56:94–110. https://doi.org/10.1016/j.peptides.2014.03.021

    Article  PubMed  CAS  Google Scholar 

  3. Kumar KG, Trevaskis JL, Lam DD et al (2008) Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 8:468–481. https://doi.org/10.1016/j.cmet.2008.10.011

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Kumar K, Zhang J, Gao S et al (2012) Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring, Md) 20:1394–1402. https://doi.org/10.1038/oby.2012.31

    Article  CAS  Google Scholar 

  5. Choi H-N, Yim J-E (2018) Plasma adropin as a potential marker predicting obesity and obesity-associated cancer in korean patients with type 2 diabetes mellitus. J Cancer Prev 23:191

    Article  Google Scholar 

  6. Jasaszwili M, Wojciechowicz T, Billert M et al (2019) Effects of adropin on proliferation and differentiation of 3T3-L1 cells and rat primary preadipocytes. Mol Cell Endocrinol 496:110532

    Article  CAS  Google Scholar 

  7. O’Dowd BF, Nguyen T, Lynch KR et al (1996) A novel gene codes for a putative G protein-coupled receptor with an abundant expression in brain. FEBS Lett 394:325–329

    Article  Google Scholar 

  8. Stein LM, Yosten GL, Samson WK (2016) Adropin acts in brain to inhibit water drinking: potential interaction with the orphan G protein-coupled receptor, GPR19. Am J Physiol-Regul Integr Comp Phys 310:R476–R480

    Article  Google Scholar 

  9. Thapa D, Stoner MW, Zhang M et al (2018) Adropin regulates pyruvate dehydrogenase in cardiac cells via a novel GPCR-MAPK-PDK4 signaling pathway. Redox Biol 18:25–32. https://doi.org/10.1016/j.redox.2018.06.003

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Hoffmeister-Ullerich SA, Süsens U, Schaller HC (2004) The orphan G-protein-coupled receptor GPR19 is expressed predominantly in neuronal cells during mouse embryogenesis. Cell Tissue Res 318:459–463. https://doi.org/10.1007/s00441-004-0948-9

    Article  PubMed  CAS  Google Scholar 

  11. Rao A, Herr DR (2017) G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. Biochim Biophys Acta Mol Cell Res 1864:1318–1327. https://doi.org/10.1016/j.bbamcr.2017.05.001

    Article  PubMed  CAS  Google Scholar 

  12. Nergiz S, Altinkaya SO, Kurt Ömürlü İ et al (2015) Circulating adropin levels in patients with endometrium cancer. Gynecol Endocrinol 31:730–735

    Article  CAS  Google Scholar 

  13. Yosaee S, Khodadost M, Esteghamati A et al (2017) Metabolic syndrome patients have lower levels of adropin when compared with healthy overweight/obese and lean subjects. Am J Mens Health 11:426–434. https://doi.org/10.1177/1557988316664074

    Article  PubMed  Google Scholar 

  14. Zang H, Jiang F, Cheng X et al (2018) Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocr J 65:685–691

    Article  CAS  Google Scholar 

  15. Butler AA, Tam CS, Stanhope KL et al (2012) Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab 97:3783–3791

    Article  CAS  Google Scholar 

  16. Sayın O, Tokgöz Y, Arslan N (2014) Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab 27:479–484

    Article  CAS  Google Scholar 

  17. Bousmpoula A, Kouskouni E, Benidis E et al (2018) Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with lipoprotein lipid profiles. Gynecol Endocrinol 34:153–156

    Article  CAS  Google Scholar 

  18. Topuz M, Celik A, Aslantas T et al (2013) Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med 61:1161–1164

    Article  CAS  Google Scholar 

  19. Inal ZO, Erdem S, Gederet Y et al (2018) The impact of serum adropin and ischemia modified albumin levels based on BMI in PCOS. Endokrynol Pol 69:135–141. https://doi.org/10.5603/EP.a2018.0002

    Article  PubMed  CAS  Google Scholar 

  20. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34

    Article  Google Scholar 

  21. Wells GA, Shea B, O’Connell D et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford

  22. Egger M, Davey-Smith G, Altman D (2008) Systematic reviews in health care: meta-analysis in context. Wiley

    Google Scholar 

  23. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558

    Article  Google Scholar 

  24. Egger M, Smith GD, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  CAS  Google Scholar 

  25. Chen R-M, Yuan X, Ouyang Q et al (2019) Adropin and glucagon-like peptide-2 are associated with glucose metabolism in obese children. World J Pediatr 15:565–571

    Article  CAS  Google Scholar 

  26. Guillemot-Legris O, Mutemberezi V, Cani PD et al (2016) Obesity is associated with changes in oxysterol metabolism and levels in mice liver, hypothalamus, adipose tissue and plasma. Sci Rep 6:1–11

    Article  CAS  Google Scholar 

  27. Kalaany NY, Gauthier KC, Zavacki AM et al (2005) LXRs regulate the balance between fat storage and oxidation. Cell Metab 1:231–244

    Article  CAS  Google Scholar 

  28. Wu L, Fang J, Chen L et al (2014) Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med 52:751–758

    Article  PubMed  CAS  Google Scholar 

  29. Bozic J, Borovac JA, Galic T et al (2018) Adropin and inflammation biomarker levels in male patients with obstructive sleep apnea: a link with glucose metabolism and sleep parameters. J Clin Sleep Med 14:1109–1118. https://doi.org/10.5664/jcsm.7204

    Article  PubMed  PubMed Central  Google Scholar 

  30. Brnić D, Martinovic D, Zivkovic PM et al (2020) Serum adropin levels are reduced in patients with inflammatory bowel diseases. Sci Rep 10:1–9

    Article  CAS  Google Scholar 

  31. Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355

    Article  CAS  Google Scholar 

  32. Kuloglu T, Aydin S (2014) Immunohistochemical expressions of adropin and ınducible nitric oxide synthase in renal tissues of rats with streptozotocin-ınduced experimental diabetes. Biotech Histochem 89:104–110

    Article  CAS  Google Scholar 

  33. Chen S, Zeng K, Liu Q-c et al (2017) Adropin deficiency worsens HFD-induced metabolic defects. Cell Death Dis 8:e3008

    Article  CAS  Google Scholar 

  34. Hu W, Chen L (2016) Association of serum adropin concentrations with diabetic nephropathy. Mediat Inflamm 2016:1–5

    Google Scholar 

  35. Redman LM, Ravussin E (2009) Endocrine alterations in response to calorie restriction in humans. Mol Cell Endocrinol 299:129–136. https://doi.org/10.1016/j.mce.2008.10.014

    Article  PubMed  CAS  Google Scholar 

  36. Lian W, Gu X, Qin Y et al (2011) Elevated plasma levels of adropin in heart failure patients. Intern Med 50:1523–1527

    Article  CAS  Google Scholar 

Download references

Funding

This work was funded by the Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Author information

Authors and Affiliations

  1. Yazd Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

    Sepideh Soltani

  2. Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran

    Roya Kolahdouz-Mohammadi

  3. Department of Medical Biochemistry, Firat Hormone Research Group), School of Medicine, Firat University, Elazig, Turkey

    Suleyman Aydin

  4. Department of Nutrition Sciences, School of Health, Larestan University of Medical Sciences, Larestan, Iran

    Somaye Yosaee

  5. Centre for Intelligent Healthcare, Coventry University, Coventry, CV1 5FB, UK

    Cain C. T. Clark

  6. Department of Nutrition and Public Health, School of Public Health, North Khorasan University of Medical Sciences, 74877-94149, Bojnurd, Iran

    Shima Abdollahi

Authors
  1. Sepideh Soltani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roya Kolahdouz-Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suleyman Aydin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Somaye Yosaee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cain C. T. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shima Abdollahi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SS conceived and designed the study; SS and SY conducted a systematic search, screened articles, and selected eligible articles; SS and RKM extracted the information from eligible studies and performed quality assessments; SS and ShA performed analyses and interpreted the results; SS, RKM, SY, SA, and SA wrote the first draft of the manuscript; CC edited the manuscript; and SA critically revised the manuscript and is the guarantor. All authors have read and approved the final manuscript. All authors had full access to all the data and take responsibility for the integrity of the data and the accuracy of the data analysis.

Corresponding author

Correspondence to Shima Abdollahi.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 184 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soltani, S., Kolahdouz-Mohammadi, R., Aydin, S. et al. Circulating levels of adropin and overweight/obesity: a systematic review and meta-analysis of observational studies. Hormones 21, 15–22 (2022). https://doi.org/10.1007/s42000-021-00331-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42000-021-00331-0

Keywords

Search

Navigation